[1]杨玉玲,王照岩,杨志一,等.miR-125a-5p通过PI3K/Akt/MMP信号通路抑制乳腺癌细胞的侵袭与转移[J].中国药理学通报,2018,(08):1145-1149.[doi:10.3969/j.issn.1001-1978.2018.08.022]
 YANG Yu-ling,WANG Zhao-yan,YANG Zhi-yi,et al.miR-125a-5p inhibits invasion and metastasis of breast cancer through PI3K/Akt/MMP signal pathway[J].Chinese Pharmacological Bulletin,2018,(08):1145-1149.[doi:10.3969/j.issn.1001-1978.2018.08.022]
点击复制

miR-125a-5p通过PI3K/Akt/MMP信号通路抑制乳腺癌细胞的侵袭与转移()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年08期
页码:
1145-1149
栏目:
论著
出版日期:
2018-08-26

文章信息/Info

Title:
miR-125a-5p inhibits invasion and metastasis of breast cancer through PI3K/Akt/MMP signal pathway
文章编号:
1001-1978(2018)08-1145-05
作者:
杨玉玲1王照岩1杨志一1李洪利2尹崇高3刘雨清1
潍坊医学院 1.临床医学院病理学教研室、2.医学研究实验中心、3.护理学院,山东 潍坊 261053
Author(s):
YANG Yu-ling1 WANG Zhao-yan1 YANG Zhi-yi1 LI Hong-li2 YIN Chong-gao3 LIU Yu-qing1
1.Dept of Pathology, College of Clinical Medicine, 2.Medical Research Center, 3.College of Nursing, Weifang Medical University, Weifang Shandong 261053, China
关键词:
乳腺癌 miR-125a-5p PI3K/Akt MMP-2 MMP-9 侵袭 转移
Keywords:
breast cancer miR-125a-5p PI3K/Akt MMP-2 MMP-9 invasion metastasis
分类号:
R329.25; R73-37; R735.902.2; R977.3; R977.6
DOI:
10.3969/j.issn.1001-1978.2018.08.022
文献标志码:
A
摘要:
目的 探讨miR-125a-5p抑制乳腺癌细胞侵袭与转移的潜在机制。方法 采用实时荧光定量PCR检测组织及细胞中miR-125a-5p的表达量; 利用瞬时转染技术将过表达质粒转染到MDA231中,Transwell侵袭实验检测miR-125a-5p对各组细胞侵袭的影响; Western blot检测各组细胞Akt的磷酸化情况,以及基质金属蛋白酶2(matrix metalloproteinase 2, MMP-2)、MMP-9的表达量。结果 通过临床标本的相关检测发现,miR-125a-5p在乳腺癌组织中的表达量明显低于癌旁相对正常组织,并且与淋巴结转移等有关。体外细胞培养实验发现,过表达miR-125a-5p细胞组的侵袭能力明显降低,Akt的磷酸化明显减弱,并且MMP-2和 MMP-9表达量下降; 而同时过表达GRB相关蛋白2(GRB-associated binding protein 2,GAB2)和miR-125a-5p细胞组的侵袭能力明显增强,Akt的磷酸化明显增强,并且MMP-2和MMP-9表达量明显升高,揭示了GAB2和miR-125a-5p共同通过PI3K/Akt通路影响MMP-2和MMP-9的表达。结论 miR-125a-5p能够通过PI3K/Akt/MMP信号通路,抑制乳腺癌细胞的侵袭与转移。
Abstract:
AimTo investigate the potential mechanism of miR-125a-5p inhibiting invasion and metastasis of breast cancer cells.Methods qRT-PCR was used to detect the expression of miR-125a-5p in tissues and cells.The transient transfection technique was used to transfect the overexpressed plasmid into MDA231.Transwell invasion assay was used to detect the effect of miR-125a-5p on invasion ability of breast cancer cells in each group.Western blot was used to detect the phosphorylation level of Akt, the expression of matrix metalloproteinase 2(MMP-2)and matrix metalloproteinase 9(MMP-9)in each group of breast cancer cells.Results Results of clinical specimens detection showed that the expression of miR-125a-5p in breast cancer tissues was significantly lower than that in adjacent normal tissues, which was related with lymph node metastasis.In vitro cell culture experiment showed that the invasion ability of the cells transfected with miR-125a-5p was significantly reduced, the phosphorylation of Akt significantly decreased, and the expression of MMP-2 and MMP-9 was down-regulated.At the same time, the invasion of the cells transfected with GRB associated-binding protein 2(GAB2)and miR-125a-5p was significantly enhanced, Akt phosphorylation was boosted obviously, and the expression of MMP-2 and MMP-9 increased significantly.It revealed that GAB2 and miR-125a-5p jointly passed through the PI3K/Akt pathway, thus affecting the changes of MMP-2 and MMP-9.Conclusion miR-125a-5p inhibits the invasion and metastasis of breast cancer through PI3K/Akt/MMP signal pathway.

参考文献/References:

[1] Rupaimoole R, Slack F J.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases [J].Nat Rev Drug Discov, 2017,16(3): 203-22.
[2] Zhou J, Zhao T, Ma L, et al.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling[J].Oncotarget, 2017, 8(61):103167-81.
[3] Zhang N, Ma D, Wang L, et al.Insufficient radiofrequency ablation treated hepatocellular carcinoma cells promote metastasis by up-regulation ITGB3[J].Cancer, 2017, 8(18): 3742-54.
[4] 徐新伟, 李佩瑞, 张增山,等.miR-125a-5p通过靶向调控GAB2抑制乳腺癌细胞的迁移能力[J].中国生物化学与分子生物学报, 2017, 33(9): 925-30.
[4] Xu X W, Li P R, Zhang Z S, et al.miR-125a-5p inhibits the migration of breast cancer cells by targeting GAB2 [J].Chin J Biochem Mol Biol, 2017, 33(9): 925-30.
[5] 田红艳, 陈萍萍, 李 笑, 等.Gab2 通过PI3K/Akt/ARK5/MMP途径影响乳腺癌的侵袭和转移[J].中国药理学通报, 2015, 31(7): 1014-8.
[5] Tian H Y, Chen P P, Li X, et al.Gab2 effects the invasion and metastasis of breast carcinoma through PI3K/Akt/ARK5/MMP signal pathway[J].Chin Pharmacol Bull, 2015,31(7): 1014-8.
[6] Sun L, Zhang B, Liu Y,et al.MiR-125a-5p acting as a novel Gab2 suppressor inhibits invasion of glioma[J].Mol Carcinog, 2016, 55(1): 40-51.
[7] Mukherjee D, Zhao J.The role of chemokine receptor CXCR4 in breast cancer metastasis[J].Am J Cancer Res, 2013, 3(1): 46-57.
[8] Long M, Zhan M, Xu S, et al.miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer[J].Mol Cancer, 2017, 16(1): 167-80.
[9] Zhu W Y, Luo B, An J Y, et al.Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer[J].Cancer Invest, 2014, 32(8): 394-401.
[10] Banerjee S, Cui H, Xie N, et al.miR-125a-5p regulates differential activation of macrophages and inflammation[J].J Biol Chem, 2013, 288(49): 35428-36.
[11] Tang H, Li R P, Liang P, et al.miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway[J].Oncol Lett, 2015, 10(2): 681-6.
[12] Zheng J, Zhou Z, Xu Z, et al.Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression[J].Mol Med Rep, 2015, 12(1): 1584-90.
[13] Nishida N, Mimori K, Fabbri M, et al.MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab[J].Clin Cancer Res, 2011, 17(9): 2725-33.
[14] Fassan M, Pizzi M, Realdon S, et al.The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis[J].Hum Pathol, 2013, 44(9): 1804-10.

相似文献/References:

[1]沈国栋,刘兢,宋礼华,等.抗ErbB2抗体曲妥珠单抗的耐药机制与展望[J].中国药理学通报,2010,(08):0.
 SHEN Guo dong,LIU Jing,SONG Li hua,et al.Mechanism and prospect of resistance to antiErbB2 antibody trastuzumab[J].Chinese Pharmacological Bulletin,2010,(08):0.
[2]刘传亮,王辉,陈伟娟,等.Snail增强乳腺癌细胞MCF7中Pgp介导的多药耐药[J].中国药理学通报,2010,(01):87.
 LIU Chuan liang,WANG Hui,CHEN Wei juan,et al.Highexpression of Snail leads to the Pgp modulateds MDR in breast cancer cell MCF7[J].Chinese Pharmacological Bulletin,2010,(08):87.
[3]张正华,梁晓华,吴学勇,等.人乳腺癌细胞株MCF7及其紫杉醇耐药株中紫杉醇结合的差异蛋白质分析[J].中国药理学通报,2010,(02):217.
 ZHANG Zheng hua,LIANG Xiao hua,WU Xue yong,et al.Analysis of the differential binding protein in human breast cancer cell line(MCF7) and paclitaxel resistant cell line(MCF7/Taxol)[J].Chinese Pharmacological Bulletin,2010,(08):217.
[4]樊春波,李少林,彭志平,等.抗CCR7单链抗体的筛选及初步鉴定[J].中国药理学通报,2010,(03):337.
 FAN Chun bo,LI Shao lin,PENG Zhi ping,et al.Screening and primary identification of antiCCR7 scFv from large phage library[J].Chinese Pharmacological Bulletin,2010,(08):337.
[5]抑制作用及其机制刘浩,蒋志文,童旭辉,等.硫酸乙酰肝素蛋白聚糖对C3H小鼠乳腺癌移植瘤的[J].中国药理学通报,2008,(06):0.
 LIU Hao,JIANG Zhi wen,TONG Xu hui,et al.Inhibitory effects of heparan sulfate proteoglycan on transplanted breast cancer in C3H mice[J].Chinese Pharmacological Bulletin,2008,(08):0.
[6]杨清玲,丁勇兴,王惠,等.抑制MCF7细胞survivin基因及对多西他赛敏感性影响[J].中国药理学通报,2008,(06):0.
 YANG Qing ling,DING Yong xing,WANG Hui,et al.Study of the RNA interference silencing of survivin gene and chemosensitivity to docetaxel in MCF7 cells[J].Chinese Pharmacological Bulletin,2008,(08):0.
[7]张小平,陶永辉,陈其亮,等.人乳腺癌细胞MCF7紫杉醇耐药株的建立及其生物学特性研究[J].中国药理学通报,2008,(06):0.
 ZHANG Xiao ping,TAO Yong hui,CHEN Qi liang,et al.Establishment and characteristics of a paclitaxel resistant human mammary adenocarcinoma cell subline (MCF7/Taxol)[J].Chinese Pharmacological Bulletin,2008,(08):0.
[8]张吉仲,刘圆,焦涛.白花丹不同有机溶剂提取物和白花丹醌对移植性乳腺癌和S180肉瘤的作用[J].中国药理学通报,2008,(08):0.
 ZHANG Ji zhong,LIU Yuan,JIAO Tao.Antitumor activity of different organic solvents extracts and plumbagin from plumbago zeylanica L.on EMT6 breast cancer and transplanting S180 in vivo[J].Chinese Pharmacological Bulletin,2008,(08):0.
[9]刘芳,高瀛岱,郭红星,等.过表达的细胞膜表面角蛋白8——乳腺癌多药耐药的一种新靶点[J].中国药理学通报,2008,(11):0.
 LIU Fang,GAO Ying dai,GUO Hong xing,et al.Overexpressive cellsurface cytokeratin 8:a noveltarget associated with multidrugresistance in human breast cancer[J].Chinese Pharmacological Bulletin,2008,(08):0.
[10]陶黎阳,符立梧.EGFR/HER2双受体酪氨酸激酶抑制剂拉帕替尼的研究进展[J].中国药理学通报,2008,(12):0.
 TAO Li yang,FU Li wu.Progress of study on lapatinib[J].Chinese Pharmacological Bulletin,2008,(08):0.

备注/Memo

备注/Memo:
收稿日期:2017-04-29,修回日期:2018-05-27
基金项目:国家自然科学基金资助项目(No 81402389,81641111,81702932); 山东省自然科学基金资助项目(No ZR2014HL077,ZR2015HL065); 山东省高等学校科技计划资助项目(No J12LK03,J13LK03)
作者简介:杨玉玲(1986-),女,硕士,研究方向:肿瘤病理学,E-mail:yylyyl8926@163.com;
尹崇高(1979-),男,硕士,副教授,研究方向:肿瘤病理学,通讯作者,E-mail: lihongli1213@sina.com;
刘雨清(1962-),女,硕士,教授,研究方向:肿瘤病理学,通讯作者,E-mail: yuqingliu89@hotmail.com
更新日期/Last Update: 2018-07-26